Analysts' Actions: JNJ MDT MSFT MA V

NEW YORK (TheStreet) -- RATINGS CHANGES

Accorda (ACOR) was upgraded at FBR Capital Markets to outperform from market perform. Valuation call, based on a $47 price target, FBR Capital Markets said.

Allegheny (ATI) was upgraded at Sterne Agee to neutral from underperform. Twelve-month price target is $39. Pricing trends are improving, Sterne Agee said.

Bloomin Brands (BLMN) was upgraded at Deutsche Bank to buy from hold. Twelve-month price target is $27. Stock is attractive, following the recent market pullback, Deutsche bank said.

Boston Scientific (BSX) was upgraded to buy at Bank of America/Merrill Lynch. Twelve-month price target is $16. Stock has come off its highs, but the company has an attractive pipeline, BofA/Merrill Lynch said.

Community Health (CYH) was upgraded at Oppenheimer to outperform from perform. Twelve-month price target is $55. Company has compelling long-term earnings growth opportunity, Oppenheimer said.

Ecopetrol (EC) was upgraded to buy at TheStreet Ratings.

Edwards Lifesciences (EW) was upgraded at J.P. Morgan to neutral from underweight. Twelve-month price target is $78. CoreValve injunction has materially altered the industry landscape, J.P. Morgan said.

Eaton Vance (EV) was upgraded at Citigroup to neutral. Twelve-month price target is $35. Stock has lagged, but the company's asset base is defensive, Citigroup said.

F5 Networks (FFIV) was upgraded at Stifel Nicolaus to buy from hold. Twelve-month price target is $120. Checks suggest higher near-term growth, Stifel Nicolaus said.

Full House Resorts (FLL) was downgraded to sell at TheStreet Ratings.

Hyatt (H) was upgraded at FBR Capital Markets to market perform from outperform. Valuation call, based on a 12-month price target of $62, FBR Capital Markets said.

Heartland Payment (HPY) was upgraded at Stifel Nicolaus to hold from sell. Stock is attractive, following a sharp selloff, Stifel Nicolaus said.

Heartware (HTWR) was upgraded at BTIG to buy. Twelve-month price target is $100. Stock is down 20% from its highs, BTIG said.

Johnson & Johnson (JNJ) was downgraded at Jefferies to hold from buy. Though company still has strong fundamentals, the valuation is too high, Jefferies said. Twelve-month price target is $105.

Eli Lilly (LLY) was upgraded at Jefferies to hold from underperform. Material downside catalysts are removed, Jefferies said. Twelve-month price target is $54.

MasterCard (MA) was upgraded at Robert Baird to outperform from neutral. Twelve-month price target is $83. Company has strong secular tailwinds and generates solid cash flow, Robert Baird said.

Medtronic (MDT) was downgraded at J.P. Morgan to neutral from overweight. Twelve-month price target is $64. CoreValve injunction adds significant risk to the model, J.P. Morgan said.

Microsoft (MSFT) was downgraded at Deutsche Bank to hold. Twelve-month price target is $42. Company lacks near-term catalysts, Deutsche Bank said.

Palo Alto Networks (PANW) was upgraded at Barclays to overweight from equal-weight. Driven by improvement in market trends, recent pullback and overhang from litigation with Juniper is in the past, Barclays said. Twelve-month price target is $78.

Transocean (RIG) was upgraded at Deutsche Bank to hold from sell. Valuation call, as the sector has underperformed for so long, Deutsche Bank said.

Seagate (STX) was upgraded at Argus to buy from hold. Stock has pulled back, but growth prospects are improving, Argus said.

Sempra Energy (SRE) was initiated at UBS with a buy rating. Company is involved with various levels of energy infrastructure with bulk of its growth tied to LNG exports, UBS said. Underlying core utility business in CA is also well-positioned, UBS said. Twelve-month price target is $106.

Visa (V) was upgraded at Robert Baird to outperform from neutral. Twelve-month price target is $245. Risk/reward has become more attractive at current levels, Baird said.

Stock Comments / EPS Changes

Atwood Oceanics (ATW) 12-month price target was lowered at Barclays to $69. Driven by lower dayrate expectations, Barclays said.

Quest Diagnostics (DGX) numbers were boosted at Credit Suisse. Twelve-month price target is now $62. Estimates were also increased given better reimbursement trends and the Solstas purchase, Credit Suisse said. Neutral rating.

International Paper (IP) 12-month price target was cut at Barclays to $54. Increased cost inputs and interrupted production, Barclays said.

JPMorgan Chase (JPM) 12-month price target was cut to $63 at UBS. EPS momentum is not robust, but company is well-capitalized and well-positioned for improving economic conditions, UBS said. Buy rating.

Wells Fargo (WFC) price target, EPS estimates were increased at UBS. First-quarter EPS beat consensus, and company is expected to remain profitable in the mortgage business, UBS said. Twelve-month price target is $50. Neutral rating.

Wells Fargo numbers were raised at Sterne Agee. Twelve-month price target is now $51. Estimates were also increased, Company continues to see healthy deposit flows and lower expenses, Sterne Agee said. Neutral rating.

Follow TheStreet on Twitter and become a fan on Facebook

This article was written by a staff member of TheStreet.

If you liked this article you might like

60 Seconds: Own Dividend Stocks And Get Paid Even When The Market Tanks

60 Seconds: Own Dividend Stocks And Get Paid Even When The Market Tanks

Jim Cramer: You Have to Decide If You Want to Profit From This Moment

Jim Cramer: You Have to Decide If You Want to Profit From This Moment

Dow Drops Over 250 Points to End Six-Session Winning Streak

Dow Drops Over 250 Points to End Six-Session Winning Streak

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here